| Drug Name |
Macitentan |
| Drug ID |
BADD_D01336 |
| Description |
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension.[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. |
| Indications and Usage |
Macitentan is indicated for the treatment of WHO group 1 pulmonary arterial hypertension (PAH) both alone and in combination with tadalafil.[L39105, L39105] |
| Marketing Status |
approved |
| ATC Code |
C02KX04 |
| DrugBank ID |
DB08932
|
| KEGG ID |
D10135
|
| MeSH ID |
C533860
|
| PubChem ID |
16004692
|
| TTD Drug ID |
D0S7JH
|
| NDC Product Code |
65015-872; 11722-058; 66215-501; 68225-070; 69037-0030; 76397-014; 59651-122; 82245-0117; 69766-006 |
| UNII |
Z9K9Y9WMVL
|
| Synonyms |
macitentan | N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide | ACT 064992 | ACT064992 | ACT-064992 | Actelion-1 | opsumit |
